Integrated transcriptomic and functional analyses identify PRR7 as a therapeutic target that associated with

Wei Sun1, Yuheng Si2, Lu Hong3

  • 1Department of Urology, The Fourth Affiliated Hospital of Anhui Medical University, 64 Chaohu North Road, Hefei, Anhui Province, China; Department of Urology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui Province, China.

Abstract

Insights

Docetaxel resistance in prostate cancer is sustained by distinct cancer cells (DRACs). The study identifies PRR7 as a key regulator of this resistance, linking genomic changes to Wnt/β-catenin signaling and stem-like traits.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Docetaxel resistance is a significant obstacle in advanced prostate cancer treatment.
  • The cellular states and molecular drivers of this resistance are not fully understood, despite research into drug efflux, apoptosis, and metabolic changes.

Purpose of the Study:

  • To identify the specific cellular states and molecular determinants that contribute to docetaxel resistance in prostate cancer.
  • To understand the mechanisms underlying chemoresistance and identify potential therapeutic targets.

Main Methods:

  • Integrated bulk RNA sequencing of docetaxel-resistant prostate cancer models with single-cell transcriptomic data from patient tumors.
  • Projected resistance-associated gene signatures onto a single-cell atlas to identify docetaxel-resistant associated cancer cells (DRACs).
  • Validated candidate regulators using molecular, cellular, and organoid-based assays in vitro and in vivo.

Main Results:

  • Identified a distinct epithelial cell cluster (DRACs) with enriched resistance-related transcriptional programs and stromal cell communication.
  • PR domain containing 7 (PRR7) was consistently upregulated in DRACs and resistant cell lines, with amplification and co-alteration in clinical datasets.
  • PRR7 inhibition suppressed Wnt/β-catenin signaling, reduced cell viability, and decreased stemness markers in resistant cells and organoids.

Conclusions:

  • DRACs represent a transcriptionally distinct subpopulation that maintains docetaxel tolerance in prostate cancer.
  • PRR7 acts as a regulatory hub, connecting genomic alterations, Wnt/β-catenin activation, and stem-like phenotypes.
  • Targeting PRR7-centered signaling presents a potential therapeutic strategy for overcoming docetaxel resistance in prostate cancer.

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...